944401-72-3

Usage

Uses

Used in Pharmaceutical Synthesis:
2-Amino-5-bromoisonicotinonitrile is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its unique structural features allow for the development of new therapeutic agents with potential applications in treating a range of diseases.
Used in Agrochemical Production:
In the agrochemical industry, 2-Amino-5-bromoisonicotinonitrile serves as a building block for the creation of new agrochemicals. Its incorporation into the molecular structures of these compounds can lead to the development of more effective pesticides, herbicides, and other agricultural chemicals that enhance crop protection and yield.
Used in Organic Compounds Synthesis:
2-Amino-5-bromoisonicotinonitrile is utilized as a starting material in the synthesis of various organic compounds. Its reactivity and structural attributes make it suitable for the preparation of a wide array of organic molecules, which can be used in different industries, including the chemical, material science, and pharmaceutical sectors.
Used in Heterocyclic Compounds Preparation:
As a versatile chemical intermediate, 2-Amino-5-bromoisonicotinonitrile is used in the preparation of heterocyclic compounds. These compounds are important in various fields, such as medicinal chemistry, where they can form the basis of new drug candidates or serve as key components in the development of novel therapeutic agents.
Used in Medicinal Chemistry and Drug Discovery:
Due to its unique structural properties, 2-Amino-5-bromoisonicotinonitrile has potential applications in medicinal chemistry and drug discovery. It can be used to explore new chemical space and identify novel bioactive molecules with potential therapeutic effects. Its ability to be modified and incorporated into diverse molecular frameworks makes it a valuable tool in the search for new drugs and treatments.

Upstream product

• 944402-16-8 2-aminoisonicotinonitrile TFA salt 
• 42182-27-4 4-cyanopyridin-2-amine 

Downstream Products

• 952206-30-3 6-bromoimidazo[1,2-a]pyridine-7-carbonitrile 
• 944401-73-4 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isonicotinonitrile 
• 952206-77-8 6-(2,4-dichloro-phenyl)-8-isobutoxy-3-(6-morpholin-4-yl-pyridin-3-yl)-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-66-5 6-(2,4-dichloro-phenyl)-8-isobutylamino-3-morpholin-4-yl-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-78-9 6-(2,4-dichloro-phenyl)-3-(2-fluoro-pyridin-4-yl)-8-isobutoxy-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-76-7 6-(2,4-dichloro-phenyl)-3-(6-fluoro-pyridin-3-yl)-8-isobutoxy-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-67-6 8-azido-6-(2,4-dichloro-phenyl)-3-morpholin-4-yl-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-65-4 8-chloro-6-(2,4-dichloro-phenyl)-3-morpholin-4-yl-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-68-7 8-amino-6-(2,4-dichloro-phenyl)-3-(morpholin-4-yl)-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-51-8 6-(2,4-dichloro-phenyl)-3-morpholin-4-yl-[1,2,4]triazolo[4,3-a]pyridine-7-carbonitrile 
• 952206-75-6 3-bromo-6-(2,4-dichloro-phenyl)-8-isobutoxy-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-54-1 6-(2,4-dichloro-phenyl)-8-isobutylamino-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-74-5 3-bromo-8-chloro-6-(2,4-dichloro-phenyl)-imidazo[1,2-a]pyridine-7-carbonitrile 
• 952206-55-2 8-azido-6-(2,4-dichloro-phenyl)-imidazo[1,2-a]pyridine-7-carbonitrile 

Relevant academic research and scientific papers

HPK1 ANTAGONISTS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

Design, synthesis, and biological evaluation of novel imidazo[1,2-a]pyridine derivatives as potent c-met inhibitors

A series of imidazo[1,2-a]pyridine derivatives against c-Met was designed by means of bioisosteric replacement. In this study, a selective, potent c-Met inhibitor, 22e was identified, with IC50 values of 3.9 nM against c-Met kinase and 45.0 nM

A mild method for the regioselective bromination of 2-aminopyridines

An efficient and regioselective bromination of 2-aminopyridines was developed. The environmental friendly bromination occurs under mild and clean conditions using readily available 1-butylpyridinium bromide as the bromine source and hydrogen peroxide as the green oxidant.

METHOD OF INHIBITING HAMARTOMA TUMOR CELLS

Dimorpholinopyrimidines are useful for inhibiting growth or proliferation of hamartoma tumor cells. Because the Dimorpholinopyrimidines inhibit the growth and proliferation of hamartoma tumor cells they are also useful in treating PTEN hamartoma tumor syndromes. The therapeutic and prophylactic treatments provided by this invention are practiced by administering to a patient in need thereof an amount of a compound of dimorpholinopyrimidine derivative that is effective to inhibit growth or proliferation of the hamartoma tumor cells.

Identification of NVP-BKM120 as a potent, selective, orally bioavailable class i PI3 kinase inhibitor for treating cancer

Phosphoinositide-3-kinases (PI3Ks) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent. The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma). These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clinical trials for the treatment of cancer.

PYRIMIDINE DERIVATIVES USED AS PI-3 KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

ORGANIC COMPOUNDS

New compounds of the Formula (I) for the treatment of non-insulin-dependent diabetes mellitus.